| 0.3268 0.011 (3.35%) | 04-07 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term | |
|||
| Targets | 6-month : | 0.44 | 1-year : | 0.49 |
| Resists | First : | 0.37 | Second : | 0.41 |
| Pivot price | 0.33  |
|||
| Supports | First : | 0.31 | Second : | 0.25 |
| MAs | MA(5) : | 0.32 |
MA(20) : | 0.35 |
| MA(100) : | 0.92 |
MA(250) : | 1.62 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 14.5 |
D(3) : | 13.9 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 3.04 | Low : | 0.2 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MREO ] has closed above bottom band by 44.2%. Bollinger Bands are 90% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 51 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 0.34 - 0.34 | 0.34 - 0.34 |
| Low: | 0.31 - 0.31 | 0.31 - 0.31 |
| Close: | 0.33 - 0.33 | 0.33 - 0.34 |
Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom and internationally. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), a novel antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 antitrypsin deficiency. The company has a collaboration with The University of Texas MD Anderson Cancer Center to evaluate anti-TIGIT therapeutic antibody candidate, etigilimab. Mereo BioPharma Group plc was incorporated in 2015 and is based in London, the United Kingdom.
Mon, 06 Apr 2026
Class Action Filed Against Mereo BioPharma Group plc (MREO) - GlobeNewswire
Mon, 06 Apr 2026
MREO DEADLINE TODAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Mereo BioPharma Group plc ... - Bluefield Daily Telegraph
Mon, 06 Apr 2026
Mereo BioPharma Investors Face Deadline for Securities Lawsuit - National Today
Mon, 06 Apr 2026
MEREO LAWSUIT DEADLINE TODAY: Bragar Eagel & Squire, P.C. - GlobeNewswire
Mon, 06 Apr 2026
MREO Investors Have Opportunity to Lead Mereo BioPharma Group plc Securities Fraud Lawsuit with the Schall Law Firm - prnewswire.com
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 160 (M) |
| Held by Insiders | 5.7233e+008 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 14,090 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -3.794e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | 0 % |
| Operating Margin | -7 % |
| Return on Assets (ttm) | 711.4 % |
| Return on Equity (ttm) | -39.5 % |
| Qtrly Rev. Growth | 500000 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | -249.13 |
| EBITDA (p.s.) | 1.11212e+006 |
| Qtrly Earnings Growth | -0.3 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -31 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | -0.01 |
| Price to Cash Flow | 0.42 |
| Dividend | 0 |
| Forward Dividend | 1.126e+007 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|